CORDIS
EU research results

CORDIS

English EN
CONnective TIssue CAncers NETwork to integrate European Experience in Adults and Children

CONnective TIssue CAncers NETwork to integrate European Experience in Adults and Children

Objective

Connective tissue cancers and more specifically sarcomas, GIST, aggressive fibromatosis and hamartomas, are uncommon cancers with an incidence below 2/100 000/year in the EU affecting children, young adults and adults. At a national level, the limited num ber of cases (about 7-10 000 in Europe each year) does notallow Europe to have a critical mass of researchers and the supporting environment to progress in disease understanding and management and have access to new drugs and treatments. Europe has prove n with research made on GIST or through the EORTC-STBSG group that gathering workforces can achieve significant progress. CONTICANET will create the critical mass of key stakeholders to overcome the current difficulties in terms of lack of data and data fragmentation, mobility of researchers, heterogeneity of methodologies and legislations. CONTICANET will 1) start by providing the required environment for developing joint research activities through the development of standard operating procedures, di stributed databases, tissue banks and harmonisation of research projects, then 2) provide the infrastructure to test several drug candidates and perform European wide clinical trials while implementing a federated research policy to 3) further lead to an integrated sustainable structure a European research foundation able to support integrated research actions and make available new treatments. Involving 20 partners major comprehensive cancer centres, academia and private companies over 5 years, CONTICAN ET will gather the critical mass of resources and knowledge in the understanding, diagnosis and management of connective tissue cancers, opening new therapeutic options. CONTICANET will spread excellence in several directions: enlarging the network with ot her academic and private organisations; developing relationship with EMEA, health authorities and insurances; supporting and collaborating with patients through advocacy groups or cancer leagues.

Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITÉ CLAUDE BERNARD LYON 1

Address

43 Bd Du 11 Novembre 1918
Lyon

France

Administrative Contact

Jean-Yves BLAY (Professor)

Participants (20)

Sort alphabetically

Expand all

ALLGEMEINES KRANKENHAUS ST GEORG

Germany

NATIONAL UNIVERSITY OF IRELAND, CORK - UNIVERSITY COLLEGE CORK

Ireland

ERASMUS MEDISCH CENTRUM

Netherlands

THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL

United Kingdom

INSTITUT GUSTAVE ROUSSY

France

FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"

Italy

IPSOGEN SAS

France

INSTITUTE OF ONCOLOGY LJUBLJANA

Slovenia

PHARMAMAR SOCIEDAD ANONIMA SOCIEDAD UNIPERSONAL

Spain

SANOFI-AVENTIS

France

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

CENTRE HOSPITALO-UNIVERSITAIRE SAINT LOUIS

France

ARTTIC

France

EZUS LYON 1

France

INSTITUT CURIE

France

ECOLE NORMALE SUPÉRIEURE DE CACHAN

France

INSTITUT BERGONIÉ

France

LYON 1 INGÉNIERIE

France

RUPRECHT-KARLS-UNIVERSITÄT HEIDELBERG

Germany

UNIVERSITÀ DEGLI STUDI DI PADOVA

Italy

Project information

Grant agreement ID: 18806

  • Start date

    1 February 2006

  • End date

    31 July 2011

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 12 748 416

  • EU contribution

    € 9 432 600

Coordinated by:

UNIVERSITÉ CLAUDE BERNARD LYON 1

France